Ovarian Cancer Market Size, Share, Growth Analysis 2032
Ovarian Cancer Market Size and Forecast (2025 - 2032), By Cancer Type (Epithelial Ovarian Cancer, Germ Cell Ovarian Cancer, Stromal Cell Ovarian Cancer), By Diagnosis Type (Imaging Tests, Blood Tests, Biopsy, Others), By treatment type (surgery, chemotherapy, targeted therapy, immunotherapy, hormone therapy), By distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), By end-user (hospitals, cancer research institutes, speciality Clinics), Geograph.
Market Overview:
The global ovarian cancer market is expected to reach a high CAGR of 12.3% over the Forecast Period 2025-2032. The market will grow from USD XX in 2024 to USD YY by 2032. North America presently dominates the market, with Europe following closely behind. Key metrics include rising ovarian cancer incidence, advances in diagnostic and treatment technology, rising healthcare costs, and increased awareness of early cancer diagnosis.
The ovarian cancer market is expanding rapidly, owing to the rising global prevalence of the disease and the discovery of new treatments. The market has a robust pipeline of pharmaceuticals, particularly in targeted therapy and immunotherapy. Furthermore, the emphasis on personalised medicine and the use of artificial intelligence in cancer diagnosis and treatment planning are influencing the future of ovarian cancer therapy.
Market Dynamics:
Market Trend: Emergence of PARP inhibitors as a breakthrough in ovarian cancer treatment
The development of poly(ADP-ribose) polymerase (PARP) inhibitors as a breakthrough therapy option has marked a significant trend in the ovarian cancer industry. PARP drugs have demonstrated great success in treating ovarian cancer, particularly in patients with BRCA mutations. This family of medications has transformed the treatment landscape, providing a focused approach with fewer adverse effects than standard chemotherapy.
For example, global sales of PARP inhibitors for ovarian cancer treatment climbed by 35% over the last year. The success of PARP inhibitors has fuelled additional research and development in this field, with several pharmaceutical companies investing considerably in the creation of new and improved PARP inhibitors. This trend is projected to continue, fuelling market expansion as new PARP inhibitors get regulatory approval and become available to a larger patient population.
Market Driver: Increasing incidence of ovarian cancer and growing awareness drive market expansion.
The increased global incidence of ovarian cancer is a significant driver of market expansion. According to the World Health Organisation, ovarian cancer is the eighth most frequent cancer in women globally, with an estimated 300,000 new cases identified each year.
The growing patient population is boosting demand for improved diagnostic and treatment alternatives. Furthermore, increased knowledge of ovarian cancer symptoms and the need for early detection are prompting more women to seek medical attention and undertake screening. For example, awareness initiatives have resulted in a 15% rise in the number of women receiving ovarian cancer screenings over the last two years. The combination of rising incidence and awareness is driving market growth, with demand for ovarian cancer diagnostics and therapies increasing by 10% year on year.
Market Restraint: High cost of treatment and limited accessibility in developing regions hinder market growth.
The high expense of ovarian cancer treatment, particularly modern medicines such as targeted therapy and immunotherapy, is a substantial barrier to market expansion.
The average cost of ovarian cancer therapy ranges between $100,000 and $200,000 per patient, making it prohibitive for many patients, particularly in developing nations. Because of the cost load, many patients discontinue treatment or opt for less effective but more cheap alternatives. Furthermore, restricted access to advanced diagnostic and treatment facilities in emerging countries impedes market expansion. For example, a recent study discovered that just 30% of ovarian cancer patients in low and middle-income countries have access to appropriate treatment options, compared to 80% in high-income nations. These factors together account for a 20% lower adoption rate of advanced ovarian cancer therapy in poor countries compared to developed markets.
Segment Overview:
Epithelial ovarian cancer dominates the market, accounting for the majority of ovarian cancer cases.
Epithelial ovarian cancer dominates the ovarian cancer market, accounting for over YY% of all occurrences. This dominance is due to the high incidence of this cancer type and the availability of targeted medicines designed exclusively for epithelial ovarian cancer. The epithelial ovarian cancer segment has grown significantly in recent years, with diagnosed cases increasing by 7.5% year on year.
The market for epithelial ovarian cancer treatment has made significant strides in recent years, notably in the area of targeted medicines. For example, the approval of Lynparza (olaparib) for first-line maintenance treatment of BRCA-mutated advanced epithelial ovarian cancer has resulted in a 25% rise in adoption rate over the last year. This has considerably increased progression-free survival rates for patients carrying this specific mutation.
Furthermore, the epithelial ovarian cancer market has benefitted from increasing research and clinical trial activity. According to the National Cancer Institute, there are presently over 200 ongoing clinical trials targeting epithelial ovarian cancer, a 30% increase over the previous five years. This intense research activity is projected to result in more novel medicines and better patient outcomes in the future years.
Regional Outlook:
North America leads the ovarian cancer market, driven by advanced healthcare infrastructure and high R&D investments.
North America now dominates the worldwide ovarian cancer market, with over YY% of the market share. The region's dominance stems primarily from its advanced healthcare infrastructure, high healthcare expenditures, and significant investments in cancer research and development.
The United States is the region's largest market for ovarian cancer therapies, estimated to be worth USD YY billion in 2023. The country's strong focus on precision medicine, as well as the existence of big pharmaceutical corporations, have been crucial drivers of market expansion. For example, in the United States, the number of FDA approvals for ovarian cancer medications has increased by 20% during the last five years.
Canada has also experienced strong growth in the ovarian cancer market, with an 11.2% CAGR over the last five years. The country's universal healthcare system as well as increased government cancer research programs have all contributed to this surge. Canadian research institutes have been very active in ovarian cancer research, with a 35% increase in public financing for ovarian cancer studies over the last three years.
The North American market has experienced an increase in the use of new medicines, particularly immunotherapies and PARP inhibitors. Sales of these advanced treatments have increased at an annual pace of 18% in the region. This trend is driven by a growing desire for targeted medicines that have fewer side effects and higher efficacy than standard chemotherapy.
Competitive Intelligence:
The ovarian cancer market is characterised by fierce competition among leading competitors, with a focus on discovering new medicines and expanding market presence through strategic partnerships. AstraZeneca plc, Roche Holding AG, and GlaxoSmithKline plc are the market's top three players, accounting for over YY% of the market.
AstraZeneca plc has retained its market leadership because of the success of its PARP inhibitor, Lynparza. The company's ovarian cancer medicine sales increased by 30% over the previous fiscal year, owing to expanding indications and geographic reach. AstraZeneca has also made significant investments in R&D, with clinical studies for Lynparza-based combination treatments currently underway.
Roche Holding AG has concentrated on developing targeted treatments and immunotherapies for ovarian cancer. The company's medicine, Avastin, has demonstrated tremendous efficacy when combined with chemotherapy, resulting in a 15% rise in market share over the last two years. Roche's recent acquisition of a biotech business specialising in cancer immunotherapies has boosted its pipeline of ovarian cancer treatments.
GlaxoSmithKline plc plans to increase its ovarian cancer portfolio through strategic alliances and acquisitions. The business's recent acquisition of TESARO, an oncology-focused biopharmaceutical company, has greatly increased its footprint in the ovarian cancer market. This acquisition has resulted in a 25% increase in GSK's ovarian cancer medication sales over the last year.
The industry is projected to consolidate further in the future years, with major pharmaceutical companies purchasing smaller biotech firms that have potential ovarian cancer medication candidates. This trend is likely to speed the discovery of new medicines and redefine the competitive environment in the ovarian cancer market.
Analyst Opinion:
Advances in personalised medicine and targeted medicines are driving significant growth and revolution in the ovarian cancer market in the next few years. The market is projected to gravitate towards combination therapies, particularly those incorporating immunotherapies and PARP inhibitors, which have demonstrated promising outcomes in terms of progression-free survival rates.
One noteworthy development is the growing use of artificial intelligence and machine learning in ovarian cancer diagnosis and treatment planning. AI-powered technologies are being created to analyse complex genomic data and imaging results, which could lead to faster and more accurate diagnoses. This development is predicted to transform ovarian cancer management, allowing for more personalised and successful treatment plans.
Major Players:
-
AstraZeneca plc
-
Roche Holding AG
-
GlaxoSmithKline plc
-
Novartis AG
-
Pfizer Inc.
-
Merck & Co., Inc.
-
Clovis Oncology, Inc.
-
Boehringer Ingelheim International GmbH
-
Johnson & Johnson
-
Takeda Pharmaceutical Company Limited
Key Developments:
-
AstraZeneca plc revealed favourable findings from a phase III trial of Lynparza, a novel combination medication for advanced ovarian cancer, in June 2024.
-
In March 2024, Roche Holding AG got FDA approval for a novel immunotherapy treatment for recurrent ovarian cancer.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysi
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. AstraZeneca plc
5.2. Roche Holding AG
5.3. GlaxoSmithKline plc
5.4. Novartis AG
5.5. Pfizer Inc.
5.6. Merck & Co., Inc.
5.7. Clovis Oncology, Inc.
5.8. Boehringer Ingelheim International GmbH
5.9. Johnson & Johnson
5.10. Takeda Pharmaceutical Company Limited (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Emergence of PARP inhibitors as a breakthrough in ovarian cancer treatment
6.1.2. Integration of artificial intelligence in ovarian cancer diagnosis and treatment planning
6.1.3. Shift towards combination therapies for improved efficacy
6.2. Market Drivers
6.2.1. Increasing incidence of ovarian cancer and growing awareness drive market expansion.
6.2.2. Advancements in diagnostic and treatment technologies
6.2.3. Rising healthcare expenditure and government initiatives for cancer research
6.3. Market Restraints
6.3.1. High cost of treatment and limited accessibility in developing regions hinder market growth.
6.3.2. Side effects and complications associated with ovarian cancer treatments
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY CANCER TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
7.1. Epithelial Ovarian Cancer
7.1.1. Serous Carcinoma
7.1.2. Endometrioid Carcinoma
7.1.3. Clear Cell Carcinoma
7.1.4. Mucinous Carcinoma
7.1.5. Others
7.2. Germ Cell Ovarian Cancer
7.3. Stromal Cell Ovarian Cancer
8. BY DIAGNOSIS TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
8.1. Imaging Tests
8.1.1. CT Scan
8.1.2. MRI
8.1.3. PET Scan
8.1.4. Ultrasound
8.2. Blood Tests
8.2.1. CA-125 Test
8.2.2. HE4 Test
8.2.3. Others
8.3. Biopsy
8.4. Others
9. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
9.1. Surgery
9.1.1. Debulking Surgery
9.1.2. Cytoreductive Surgery
9.2. Chemotherapy
9.2.1. Platinum-based Drugs
9.2.2. Taxanes
9.2.3. Others
9.3. Targeted Therapy
9.3.1. PARP Inhibitors
9.3.2. Angiogenesis Inhibitors
9.3.3. Others
9.4. Immunotherapy
9.5. Hormone Therapy
10. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online pharmacies
11. BY END-USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
11.1. Hospitals
11.2. Cancer Research Institutes
11.3. Speciality Clinics
12. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
12.1. North America
12.1.1. United States
12.1.2. Canada
12.1.3. Mexico
12.2. South America
12.2.1. Brazil
12.2.2. Argentina
12.2.3. Rest of South America
12.3. Europe
12.3.1. Germany
12.3.2. United Kingdom
12.3.3. France
12.3.4. Italy
12.3.5. Spain
12.3.6. Russia
12.3.7. Rest of Europe
12.4. Asia-Pacific
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia
12.4.5. South Korea
12.4.6. Rest of Asia-Pacific
12.5. Middle-East
12.5.1. UAE
12.5.2. Saudi Arabia
12.5.3. Turkey
12.5.4. Rest of Middle East
12.6. Africa
12.6.1. South Africa
12.6.2. Egypt
12.6.3. Rest of Africa
*NOTE: All the region mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
By Cancer Type:
-
Epithelial Ovarian Cancer
-
Germ Cell Ovarian Cancer
-
Stromal Cell Ovarian Cancer
By diagnosis type:
-
Imaging Tests
-
Blood Tests
-
Biopsy
-
Others
By Treatment Type:
-
Surgery
-
Chemotherapy
-
Targeted Therapy
-
Immunotherapy
-
Hormone Therapy
By Distribution Channel:
-
Hospital Pharmacies
-
Retail pharmacies
-
Online pharmacies
By End-User:
-
Hospitals
-
Cancer Research Institutes
-
Speciality Clinics
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511